 The high prevalence of G250 in RCC, the definition of an HLA-A2-restricted epitope the most common HLA type, and its immunogenicity makes it the most attractive candidate for peptide-based vaccine approaches in RCC therapy. The promising preclinical and clinical evidence provides the rationale for the use of IL-2 to potentiate the antitumor effects of cancer vaccines. 